Partial replicate design & ABE for the FDA [Design Issues]

posted by nobody – 2017-03-06 15:18 (3383 d 03:35 ago) – Posting: # 17141
Views: 13,807

Les Benet at the BioInternational ’94 in Munich. You’ve been there…


Nice location, btw. ;-) (you still have the list of participants? ***glotz***)

...but even some 10 years ago (and later) from time to time this sentiment came up from Schlipsträgers...

Re. Test better than Ref: But you can't know in advance and if you have a look at some of the "companies" nowadays "developing" generics your "gut feeling"/experience from the past might be subjected to some change (as so many things nowadays...)

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
141 visitors (0 registered, 141 guests [including 14 identified bots]).
Forum time: 19:54 CEST (Europe/Vienna)

In theory, there is no difference between theory and practice.
But, in practice, there is.    Jan L.A. van de Snepscheut

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5